Evidence map›Paper›PMID 27161569›Full record

ArticleLung2016

Evaluation of Simvastatin and Bone Marrow-Derived Mesenchymal Stem Cell Combination Therapy on Airway Remodeling in a Mouse Asthma Model.

Maryam Mohammadian, Hamid Reza Sadeghipour, Iraj Ragerdi Kashani, Gila Pirzad Jahromi, Amene Omidi, Amir Kavian Nejad, Ravie Golchoobian, Mohammad Hossein Boskabady

Abstract read
PubMed Publisher
In one paragraph

Article in Lung, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Maryam MohammadianDepartment of Physiology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Hamid Reza SadeghipourDepartment of Physiology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Iraj Ragerdi KashaniDepartment of Anatomy, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Gila Pirzad JahromiChemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Amene OmidiDepartment of Anatomy, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Amir Kavian NejadDepartment of Emergency Medical Services, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ravie GolchoobianDepartment of Physiology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Hossein BoskabadyNeurogenic Inflammation Research Center and Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. boskabadymh@mums.ac.ir.
Tehran University of Medical Sciences · IRBaqiyatallah University of Medical Sciences · IRMashhad University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe effect of bone marrow-derived mesenchymal stem cells (BMSCs) on asthma treatment was shown in our previous study. Several studies have shown the effect of statins on BMSC preservation and migration to sites of inflammation. In this study, the effects of simvastatin and BMSC combination therapy in an ovalbumin-induced asthma model in mouse were examined.

methodsFour groups of BALB/c mice were studied including control group (animals were not sensitized), asthma group (animals were sensitized by ovalbumin), asthma + simvastatin group (asthmatic animals were treated with simvastatin), and asthma + BMSC + simvastatin group (asthmatic animals were treated with simvastatin and BMSCs). BMSCs were isolated, characterized, labeled with BrdU, and transferred into asthmatic mice. BMSC migration, airways histopathology, and total and differential white blood cell (WBC) count in bronchoalveolar lavage (BAL) fluid were evaluated.

resultsA significant increase in the number of BrdU-BMSCs was found in the lungs of mice treated with simvastatin + BMSCs compared to mice treated with BMSCs. The histopathological changes, BAL total WBC counts, and the percentage of neutrophils and eosinophils were increased in asthma group compared to the control group. Treatment with simvastatin significantly decreased airway inflammation and inflammatory cell infiltration. Combination therapy improved all measured parameters higher than simvastatin. Goblet cell hyperplasia and subepithelial fibrosis were also decreased in combination therapy group.

conclusionThese results indicated that simvastatin and BMSC combination therapy was superior to simvastatin therapy and BMSC therapy alone in reduction of airway remodeling and lung inflammation in the ovalbumin-induced asthma model in mouse.

Indexed as

Airway RemodelingMesenchymal Stem Cell TransplantationAnimalsAsthmaBronchoalveolar LavageBronchoalveolar Lavage FluidCell MovementCollagenCombined Modality TherapyDisease Models, AnimalEosinophilsFibrosisGoblet CellsHydroxymethylglutaryl-CoA Reductase InhibitorsHyperplasiaLeukocyte CountCollagenHydroxymethylglutaryl-CoA Reductase InhibitorsOvalbuminSimvastatinAirway remodelingMouse asthma modelSimvastatinStem cells

Identifiers

PMID27161569
OpenAlexW2345402153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.